Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,398.93
+0.8%
+61.82
Arrow-Thin-Down
DJI
49,609.16
+0.0%
+12.19
Arrow-Thin-Down
NASDAQ
26,247.08
+1.7%
+440.88
Arrow-Thin-Down
Bitcoin
$80,171.00
+0.2%
+$149.17
Arrow-Thin-Down
AAPL
$293.41
+2.1%
+$5.97
Arrow-Thin-Down
AMZN
$272.68
+0.6%
+$1.51
Arrow-Thin-Down
GOOG
$396.94
+0.4%
+$1.64
Arrow-Thin-Down
META
$609.53
-1.2%
-$7.28
Arrow-Thin-Down
MSFT
$415.17
-1.3%
-$5.60
Arrow-Thin-Down
NVDA
$215.16
+1.7%
+$3.66
Arrow-Thin-Down
TSLA
$427.99
+3.9%
+$16.20
Most Active StocksDaily Stock GainersDaily Stock Losers

Generate Biomedicines

(NASDAQ) GENB

Current Price$13.71
Market Cap$1.73B
Since IPO (2026)+7%
5 YearN/A
1 YearN/A
1 Month+15%

Generate Biomedicines Financials at a Glance

Market Cap

$1.73B

Revenue (TTM)

$7.22

Net Income (TTM)

$61.71

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.17 (Low)

Price

$13.71

Volume

13,525

Open

$13.74

Previous Close

$13.71

Daily Range

$13.46 - $14.64

52-Week Range

$11.00 - $15.88

GENB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Generate Biomedicines

Industry

Biotechnology

Sector

Health Care

Employees

312

CEO

Michael T. Nally, MBA

Website

generatebiomedicines.com

Headquarters

Somerville, MA 02143, US

GENB Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-7%

Net Income Margin

-6%

Return on Equity

0%

Return on Capital

-95%

Return on Assets

-62%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.73B

Shares Outstanding

127.45M

Volume

13.53K

Avg. Volume

586.87K

Financials (TTM)

Gross Profit

$31.89M

Operating Income

$235.06M

EBITDA

$208.49M

Operating Cash Flow

$200.62M

Capital Expenditure

$3.51M

Free Cash Flow

$204.13M

Cash & ST Invst.

$221.50M

Total Debt

$68.53M

Generate Biomedicines Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$7.22

N/A

Gross Profit

$3.95

N/A

Gross Margin

54.69%

N/A

Market Cap

$1.73B

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

$61.71

N/A

EBITDA

$60.84

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$160.57

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$51.31

N/A

Short Term Debt

$14.26

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

-61.64%

N/A

Free Cash Flow

$84.17

N/A

Operating Cash Flow

$80.39

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7400.12+0.01%
^DJIDJI
$49624.02+0.00%
^IXICNASDAQ
$26210.88+0.02%
BTCBitcoin
$80227.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
RXTRackspace Technology
$5.49+0.56%
NVDANvidia
$215.20+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.62+0.08%
IRENIren
$61.20+0.08%

Questions About GENB

What is the current price of Generate Biomedicines?

Generate Biomedicines is trading at $13.71 per share.

What is the 52-week range for Generate Biomedicines?

Over the past 52 weeks, Generate Biomedicines has traded between $11.00 and $15.89.

How much debt does Generate Biomedicines have?

As of the most recent reporting period, Generate Biomedicines reported total debt of $65.57M.

How much cash does Generate Biomedicines have on hand?

Generate Biomedicines reported $160.57M in cash and cash equivalents in its most recent financial results.

What is Generate Biomedicines’s dividend yield?

Generate Biomedicines does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services